Long-term Glycemic Variability and Risk of Adverse Outcomes : A Systematic Review and Meta-analysis by Gorst, Catherine et al.
Long-term glycaemic variability and risk of adverse outcomes: a systematic review and 
meta-analysis 
Short title: HbA1c variability and adverse outcomes 
Catherine Gorst MBChB,1 Chun Shing Kwok MBBS2, 3, Saadia Aslam MB ChB,4 Iain 
Buchan MD,5 Evangelos Kontopantelis PhD1,Phyo K Myint MD6, Grant Heatlie PhD2 ,Yoon 
Loke MD7 , Martin K Rutter MD,8,9 Mamas A Mamas BM BCh DPhil2,3,5 
1Institute of Population Health, Centre for Primary Care, University of Manchester, 
Manchester, UK 
2 Royal Stoke Hospital, University Hospitals of North Midlands, Stoke-on-Trent, UK 
3Keele Cardiovascular Research Group, Institutes of Science and Technology in Medicine 
and Primary Care and Health Science, University of Keele, Stoke-on-Trent, UK 
4Central University Hospitals NHS Foundation Trust, Manchester Academic Health Science 
Centre, Manchester, UK. 
5 Farr Institute, University of Manchester, UK 
6Epidemiology Group, Institute of Applied Health Sciences, School of Medicine & Dentistry, 
University of Aberdeen, Aberdeen, Scotland, United Kingdom 
7University East Anglia 
8 Manchester Diabetes Centre, Manchester, Central Manchester University Hospitals NHS 
Foundation Trust, Manchester Academic Health Science Centre, UK 
9 Centre for Endocrinology and Diabetes, Institute of Human Development, University of 
Manchester, UK 
 
Correspondence to: 
Catherine Gorst 
Institute of Population Health,  
 1 
Centre for Primary Care, 
University of Manchester,  
Williamson Building,  
Oxford Road, 
Manchester, UK, M13 9PL 
Tel:0161 2750752 
Fax:0161 2757600 
Mail to: catherine.gorst@postgrad.manchester.ac.uk 
Keywords: diabetes, HbA1c variability, cardiovascular disease, nephropathy, retinopathy 
Word count abstract: 250 
Word count main text: 3,398 
Three tables, one figure and two supplementary tables
 2 
Abstract 
Background: Glycaemic variability is emerging as a measure of glycaemic control, which 
may be a reliable predictor of complications. 
Purpose: To perform a systematic review and meta-analysis evaluating the association 
between HbA1c variability and micro- and macro-vascular complications and mortality in 
type 1 and type 2 diabetes mellitus.  
Data Sources and Study selection: MEDLINE and EMBASE were searched (2004-2015) 
for studies describing associations of HbA1c variability with adverse outcomes in patients 
with type 1 and type 2 diabetes. 
Data Extraction: Data extraction was performed independently by two reviewers. 
Data Synthesis: Random effects meta-analysis was performed with stratification according 
to the measure of HbA1c variability, method of analysis and diabetes type. Seven studies 
evaluated HbA1c variability among patients with type 1 diabetes and showed an association 
of HbA1c variability with renal disease (RR 1.56 95%CI 1.08-2.25, 2 studies), cardiovascular 
events (RR 1.98 95%CI 1.39-2.82) and retinopathy (RR 2.11 95%CI 1.54-2.89). Thirteen 
studies evaluated HbA1c variability among patients with type 2 diabetes. Higher HbA1c 
variability was associated with higher risk of renal disease (RR 1.34 95%CI 1.15-1.57, 2 
studies), macro-vascular events (RR 1.21 95%CI 1.06-1.38), ulceration/gangrene (RR 1.50 
95%CI 1.06-2.12), cardiovascular disease (RR 1.27 95%CI 1.15-1.40) and mortality (RR 
1.34 95%CI 1.18-1.53). 
Limitations: Most studies were retrospective with lack of adjustment for potential 
confounders and there was inconsistency in the definition of HbA1c variability. 
Conclusions: HbA1c variability was positively associated with micro- and macro-vascular 
complications and mortality independently of the HbA1c level and might have a future role in 
clinical risk assessment. 
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Introduction 
Current management of type 1 and type 2 diabetes uses the average glycaemia measure, 
HbA1c, to monitor control. This rationale is based on trial and observational evidence that 
showed lowering HbA1c reduced the risk of developing micro- and macro-vascular 
complications of diabetes(1)(2)(3)(4). There is current debate about whether an average 
glycaemic measure is most appropriate to assess risk for developing complications. For 
example, one analysis of the Diabetes Control and Complications Trial (DCCT) indicated 
higher rates of retinopathy in the conventional treatment group compared to the intensive 
treatment group overtime in patients with similar average HbA1c values in the two groups(5). 
This suggested that additional factors other than mean HbA1c may be responsible for this 
increased retinopathy risk(5)(6)(7). Glycaemic variability is now emerging as a possible 
additional measure of glycaemic control, which may be a better predictor of complications 
than average glycaemic measures.  
 Glycaemic variability relates to fluctuations in glycaemia. Short-term glycaemic 
variability refers to within or between day fluctuations in an individual and includes multiple 
methods of assessment. Long-term glycaemic variability refers to fluctuations over several 
weeks or months and is most commonly assessed by HbA1c variability. However neither 
have a standardized method of measurement or definition(8). A recent meta-analysis 
concluded that HbA1c variability, assessed by standard deviation (SD), is associated with 
renal disease in type 1 and type 2 diabetes(9). However, there have been no systematic 
reviews or meta-analyses evaluating the relationship between long-term glycaemic variability 
and other complications in diabetes. This is despite contradictory literature providing 
evidence in support(6,10–15) and against a relationship(16–20) with other complications in 
type 1 and type 2 diabetes.   
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 Long-term glycaemic variability is important for several reasons. Firstly, unlike short-
term glycaemic variability, long-term glycaemic variability may predict complications in 
both type 1 and type 2 diabetes(6,10–15,21–29). Secondly, HbA1c is routinely recorded in 
primary care for both types where as measures of short-term variability are not(30,31). 
Finally, it could be a potentially modifiable risk factor.  
 Here we evaluate the evidence for the association of HbA1c variability with mortality 
and complications in type 1 and type 2 diabetes to gain insight into its clinical utility to 
predict adverse outcomes by conducting a systematic review and meta-analysis.
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 Methods 
We conducted a systematic review and meta-analysis to evaluate adverse outcomes with 
HbA1c variability among patients with diabetes.  
 
Data Sources and Searches 
We conducted a search of MEDLINE and EMBASE in September 2014 using the search 
terms in Appendix 1which included a year limit 2004-current. However, to ensure 
incorporation of the most up to date literature the search was updated in July 2015.The search 
was initially conducted by CSK and duplicated to check by CG and included review of 
conference abstracts. A broad search criteria was used with three parts: diabetes related 
terms, outcomes of interest related terms and exposure related terms (HbA1c variability) and 
limited the search results to the last ten years.  
 
Study selection 
We included studies of patients with diabetes which evaluated HbA1c variability and adverse 
outcomes published within the last ten years. There were no restrictions on inclusion based 
on neither the age of the participants nor the definition of HbA1c variability. The main 
adverse outcomes of interest were renal disease (diabetic nephropathy, micro-albuminuria, 
macro-albuminuria, renal failure, chronic kidney disease), diabetic retinopathy, diabetic 
neuropathy, cardiovascular macro-vascular events (MI/IHD/heart failure/stroke/PVD) and 
death. We excluded reviews, editorials and case reports but searched the bibliographies of 
included studies and relevant reviews for additional studies. Study titles and abstracts were 
initially screened independently by two reviewers (CG and SA) and full papers of potentially 
relevant studies were downloaded and reviewed for inclusion. The final inclusion of studies 
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was made by discussion between five reviewers (CG, SA, CSK, EK, MM). See figure 1 for 
full details of study selection. 
 
Data extraction and quality assessment 
Data extraction was performed independently by two reviewers (CG and SA).  A data 
extraction sheet was developed which collected information on study design, participant 
characteristics, quality of study assessment, definitions of HbA1c variability, outcomes 
evaluated and results.  Discrepancies in extractions were discussed with two other reviewers 
(CSK and YL). 
 
Data synthesis and analysis 
We conducted random effects meta-analysis of the adjusted risk estimates (where available) 
with the inverse variance method using RevMan 5.3 (Nordic Cochrane Centre).   
 Analysis was stratified according to the measure of HbA1c variability used, the 
method of analysis used and type of diabetes. In terms of HbA1c variability, studies were 
divided into those that reported coefficient of variation (CV) and standard deviation (SD) as 
their measure of variability. Within the two groups, there was a further splitting of the 
analysis according to whether the highest variability group was compared with the lowest 
variability or whether variability was measured per incremental increase in CV or SD.  
Where possible, we chose to analyse results for the group with greater HbA1c variability 
against that of the group with lower HbA1c variability. If there were several groups with 
differing levels of variability, we conducted the meta-analysis based on the group with the 
greatest variability compared to the one with the least variability. Both SD and CV are 
measures of variability. The SD is a measure of how much values differ from the group 
mean, on average. The CV is the ratio of SD to the mean and so it is a measure that is 
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independent of the mean. The CV may be appropriate for parameters like HbA1c, the 
variability of which is likely to increase as the mean increases. However there is no 
standardized method of measurement(8). 
 Where there were insufficient studies for pooling, or significant heterogeneity that 
could not be explained, we performed narrative synthesis. 
We assumed similarity between risk ratios and odds ratios because adverse events are 
rare(32). 
 Statistical heterogeneity was assessed using the I2 statistic(33) where I2 values of 
30%–60% represented a moderate level of heterogeneity. Six sensitivity analyses were 
performed. These included prospective studies, studies that had a follow up of over five years 
and studies that adjusted for duration of diabetes, number of HbA1c measurements, 
comorbidities and baseline medications. Publication bias assessment using funnel plots was 
performed if there were more than ten studies and there was no evidence of statistical 
heterogeneity in a particular meta-analysis(34).  
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Results 
Studies included and participant characteristics 
A flow diagram was used to show the process of study selection (Figure 1).  A total of 20 
studies met the inclusion criteria with a total of 87,641 participants.  Eleven studies included 
participants from Europe (10,11,14,16–19,25,26,29,35,36),  eight from Asia 
(12,13,15,18,20,24,27,28), three from North America(23)(18)(6) and one from 
Australasia(18). The number of participants in each study ranged from 234 to 35,891 
 
Type 1 diabetes 
There were seven studies including 44,021 participants with type 1 
diabetes(25)(10)(11)(6)(29)(35)(14). These consisted of three retrospective cohort 
studies(11)(14)(25), two prospective cohort studies(10)(29),  one post hoc analysis of a 
randomized controlled trial(6) and one cross sectional study(35). Most of the studies used 
data from secondary care apart from two studies(10,11) that used primary and secondary care 
data. 
 
Type 2 diabetes 
Type 2 diabetes participants were included in 13 studies of 43,620 participants (12,13,15–
20,23,24,26–28,36). These consisted of six retrospective cohort studies(13,15,20,23,28,36), 
five prospective cohort studies(12,16,17,19,26,27), and two post hoc analyses of  randomized 
controlled trials(18)(24). All studies used secondary care data apart from one study of 
primary and secondary care data(19) and one of solely US primary care data(23). 
Details of the study design and participants are shown in Table 1. 
 
Quality assessment of included studies 
 9 
The quality assessment of included studies is shown in Table 2. For both type 1 and type 2 
diabetes the outcome assessment varied from blood and urine tests for diabetic nephropathy, 
to fundoscopy for retinopathy and formal follow up for cardiovascular events and death. The 
frequency of outcome evaluation differed depending on the study. All studies adjusted for 
mean HbA1c. 
 
Type 1 diabetes 
The shortest follow up was a mean of 5.2 years (11)  and the longest was 23 years(14).  The 
number of HbA1c measurements per patient ranged from a median of four (29) to 13(10). 
Data from all studies was unclear about loss to follow up. All the studies used some form of 
adjustment for baseline covariates, however five studies did not adjust for baseline diabetes 
medications(10)(25)(29)(11)(14) and none of the studies adjusted for baseline hypertensive 
medication. 
 
Type 2 diabetes 
 The shortest follow up was two years (20)  and the longest was a median of 15.9 years (13).  
The number of HbA1c measurements per patient ranged from three (19) to a median of 79 
(13). In six studies loss to follow up was unclear, six had less than 10% of participants lost to 
follow up while one study had 27.5% lost to follow up (13).  All the studies used some form 
of adjustment for baseline covariates, however six did not adjust for baseline diabetes 
medication (23)(24)(15)(27)(19,20) and four did not adjust for baseline hypertensive 
medication (16)(17)(27)(13)(20). Of the seven studies which did 
(28)(23)(18)(24)(12)(15)(26), only two adjusted for ACE inhibitor/ARB use(23)(24). The 
definition of glycaemic variability, outcome evaluated, study follow up and results are shown 
in Table 3. 
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 Type 1 diabetes 
Three studies evaluated adverse outcomes by considering the impact of HbA1c coefficient of 
variation(35)(14)(11) (Appendix 2 figure 2). There was no significant association between 
HbA1c CV and retinopathy (RR (95% CI): 1.34 (0.89-2.04)), 2 studies) or micro-albuminuria 
(RR 1.04 (1.00-1.08), 1 study). The study by Hermann et al however did report that HbA1c 
variability based on CV was associated with a 3.5% higher risk of diabetic retinopathy per 
one unit increase in HbA1c CV at ten years duration of diabetes(14). 
Four studies evaluated adverse outcomes associated with HbA1c standard 
deviation(6)(10)(29)(25) (Appendix 2 figure 2). All showed a significant association of 
HbA1c SD and adverse outcomes. Highest compared to lowest variation SD group was 
associated with increased risk of nephropathy (RR 1.92, 1.49-2.47) and cardiovascular events 
(RR 1.98, 1.39-2.82). Incremental increases in SD were also associated with increased risk of 
nephropathy (RR 1.86, 1.41-2.46), micro-albuminuria (RR 1.56, 1.08-2.25, 2 studies) and 
retinopathy (RR 2.11, 1.54-2.89). 
There were no studies evaluating HbA1c variability in type 1 DM and mortality.  
Sensitivity analyses for study type, studies that adjusted for duration of diabetes, 
number of HbA1c measurements, comorbidities and baseline medications produced similar 
results to those recorded with inclusion of all studies. See Supplementary Table1. 
 
Type 2 diabetes 
Studies reporting all-cause mortality as an outcome were not pooled due to high levels of 
heterogeneity. This was thought to be due to differing follow-up durations and lost to follow 
up. The outcome was therefore split according to short follow up (less than five years) and 
long follow up (five or more years).  
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Six studies evaluated adverse outcomes by considering the impact of HbA1c 
coefficient of variation (28)(26)(18)(15)(13)(36) and nine studies with HbA1c standard 
deviation(12)(26)(24)(27)(15)(13)(16)(17)(18)(20). 
 Increase in HbA1c variability defined by high versus low CV groups was associated 
with increased risk of diabetic nephropathy (RR 1.58, 1.19-2.10) and all-cause mortality in 
studies with over five years of follow up (RR 2.89, 1.45-5.74,) and in those with less than 
five years follow up (RR 1.06, 1.01-1.11)(Appendix 2 figure 3a). Incremental increases in 
CV was also associated with significantly increased risk of nephropathy (RR 1.03, 1.01-
1.05), macro/micro-vascular events (RR 1.11, 1.02-1.21), macro-vascular events (RR 1.18, 
1.04-1.33) and with mortality with over five years of follow up (1.10, 1.03-1.16) and less 
than five years of follow up (RR 1.31, 1.16,1.48). There was no significant association 
between incremental increase in CV and micro-vascular events (RR 1.07,0.96-1.20 
(Appendix 2 figure 3b). 
 Considering HbA1c variability with SD, high versus low SD group was associated 
with increased risk of nephropathy (RR 1.24, 1.02-1.51), all-cause mortality (RR 2.34, 1.48-
3.71, 2 studies), micro-albuminuria (RR 1.34, 1.15-1.57, 2 studies), macro-albuminuria (RR 
1.41, 1.03-1.93), ulceration/gangrene (RR 1.50, 1.06-2.12) and with mortality in studies with 
over five years of follow up (3.09, 1.45-6.58) and in those with less than five years of follow 
up (RR 1.99, 1.11,3.55) (Appendix 2 figure 4a). Incremental increase in SD was associated 
with an increased risk of nephropathy (RR 1.22, 1.05-1.42, 2 studies), end stage renal failure 
(RR 1.53, 1.35-1.73), micro-albuminuria (RR 1.20, 1.03-1.39), macro/micro-vascular events 
(RR 1.12, 1.02-1.22), macro-vascular events (RR 1.21, 1.06-1.38), cardiovascular disease 
(RR 1.27, 1.15-1.40) and with mortality in studies with over five years of follow up (3.17, 
1.43-7.03) and in those with less than five years of follow up (RR 1.34, 1.18,1.53). There was 
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no significant association between incremental increase in SD and micro-vascular events 
(RR1.08, 0.96-1.21) or retinopathy (RR 1.03, 0.69-1.53, 2 studies) (Appendix 2 figure 4b). 
The study by Penno et al reported additional non-significant associations with any lower limb 
vascular event, any cerebrovascular event, any coronary event, acute MI, any cardiovascular 
disease or stroke. This could not be included in the meta-analysis since raw data was not 
provided(17). Data regarding the significant association of HbA1c CV and all cause-mortality 
reported by Lang et al (RR1.02, 1.01-1.03) was not included in the meta-analysis since all 
participants had incident chronic heart failure increasing heterogeneity with other studies and 
affecting external validity(36).  
 The study by Cumming et al reported a significant worsening of one more chronic 
kidney disease stage with an average excess of HbA1c >7% (53mmol/mol) (OR 1.173, 
1.031-1.335) (23).   
Hirakawa et al also used other variability measures; HbA1c variation independent of 
the mean (VIM), HbA1c residual standard deviation (RSD) and HbA1c average real 
variability (ARV). All were significantly associated with macro-vascular complications, 
micro-vascular/macro-vascular complications and mortality using data from ADVANCE 
[VIM-HbA1c; 1.17 (1.04, 1.32), 1.11 (1.02,1.2) 1.30(1.15,1.46) RSD-HbA1c; 1.20 (1.07, 
1.35), 1.10 (1.01,1.19), 1.33(1.19,1.49). ARV-HbA1c; 1.21 (1.07, 1.37), 1.11 (1.02,1.21), 
1.38(1.22,1.55)](18). Skriver et al defined HbA1c variability as the mean absolute residual 
around the line connecting index value and closing value. They reported that for index 
HbA1c ≤8% (64 mmol/mol), variability above 0.5 was associated with increased all-cause 
mortality (HR 1.3,1.1-1.5) per HbA1c percentage point variability. However for individuals 
with index HbA1c>8% (64 mmol/mol), no association between HbA1c variability and 
mortality could be identified(19). 
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Sensitivity analyses for study type, studies that adjusted for duration of diabetes, 
number of HbA1c measurements, baseline medications and comorbidities produced similar 
results to those that included all studies (Supplementary Table 2). 
 There were too few studies in the meta-analysis to assess publication bias. 
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 Discussion 
Glycaemic variability is emerging as a measure of glycaemic control that may be an 
important predictor of complications in patients with diabetes. Our analysis suggests that 
greater HbA1c variability, irrespective of the definition used, is associated with adverse 
outcomes in several micro and macro-vascular endpoints and mortality. We report that 
HbA1c variability in type 1 and type 2 diabetes is associated with renal and cardiovascular 
disease. The former is supported by ten studies using both CV and SD as a measure of 
HbA1c variability(6,10,12,16,24–29). Only one small cross-sectional study with a paediatric 
cohort using CV did not report this significant association(35). The latter is supported by two 
studies using SD(10,12). Retinopathy appears to be associated with HbA1c variability in type 
1 diabetes(6) but not in type 2 diabetes(16)(20). However this was only shown using SD as 
measure of variability(6) and not with CV(11,14). Four studies addressed the relationship 
with mortality in type 2 diabetes(13,15,18)(19) with significant associations reported for SD 
and CV(13,15,18). Post-hoc analysis of the ADVANCE dataset showed an association in 
type 2 diabetes of HbA1c variability defined by CV and SD with macro-vascular events and 
combined micro/macro-vascular events but not with micro-vascular events(18). These 
findings were independent of mean HbA1c suggesting that HbA1c variability may be a useful 
additional risk stratification tool in both type 1 and type 2 diabetes.  
Our results add to the findings of a significant association between HbA1c SD and 
renal disease reported in the 2014 systematic review and meta-analysis by Cheng et al(9). 
This meta-analysis of eight papers assessing the relationship between HbA1c variability and 
renal disease in type 1 and type 2 diabetes has several limitations: studies were excluded that 
did not report HR (including the study by Penno et al (16)); measures of variability other than 
SD or CV were not considered; and different renal outcomes /endpoints were pooled . 
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Our results differ from the previous systematic reviews of short-term glycaemic 
variability and the risk of complications in diabetes (21)(22). In previous studies short-term 
glycaemic variability was assessed by a variety of methods including; SD, CV or mean 
amplitude of glycaemic excursions (MAGE) of daily glucose readings including SMBG (self 
monitoring of blood glucose), continuous blood glucose monitoring (CGM), fasting plasma 
glucose or postprandial glucose(21). These studies found no consistent evidence of a 
relationship between short-term glycaemic variability and the risk of any complications in 
type 1 diabetes. However, in six studies involving patients with type 2 diabetes, both previous 
reviews found a positive association between glucose variability and retinopathy. In general 
agreement with these two reviews we found a positive relationship in type 2 diabetes between 
glycaemic variability and cardiovascular disease. Our findings of a significant association 
between HbA1c variability and all-cause mortality in type 2 diabetes is consistent with the 
findings of Nalysnyk et al’s review but not with those of Smith-Palmer et al.  
 These differing risk prediction results for short- and long-term glycaemic variability 
may indicate differing pathological mechanisms. Short-term glycaemic variability has been 
postulated to induce oxidative stress, inflammatory cytokines and endothelial damage 
(37)(38–40)(41); mechanisms linked to the development of diabetes complications(42,43). 
Additional mechanisms that may explain the association of HbA1c variability and adverse 
events include:  cellular ‘metabolic memory’ (44)(45)(46)(47), insulin resistance (10)(48), 
sensitivity of HbA1c for detecting glycaemic variability(44) and the exponential relationship 
between HbA1c and risk of micro-vascular complications (44)(16).  
 Confounding factors rather than a causal relationship may explain the association of 
HbA1c variability with complications. These include poor medication compliance and self- 
management(10)(12)(28), multi-morbidity(28), certain medications such as steroids and 
antipsychotics(49), poor quality of life and lack of support (50)(51) and infections (10).  
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 Eight studies indicated HbA1c variability was superior at predicting diabetes related 
complications than mean HbA1c (6,10,12,13,17,24,25)(15). Only one study found a 
significant association of mean HbA1c with diabetes related complications but not with 
HbA1c variability(16,17). Further research is required to assess whether HbA1c variability 
might be clinically useful for risk stratification and whether it might be a valuable therapeutic 
target.  
 To our knowledge this is the first systematic review and meta-analysis of HbA1c 
variability in diabetes and risk of mortality and complications other than renal disease. 
Limitations of our analysis include: exclusion of non-English language papers and studies 
prior to 2004. However, inclusion of studies beyond the last ten years may not be 
generalizable to current practices as current therapies (long acting insulins, GLP-1 agonists 
and DDP4 inhibitors) were not available before 2004. Due to the small number of available 
studies we were unable to use meta-regression to assess study characteristics as moderators. 
Our heterogeneity estimates vary from very high to zero and it is often argued that highly 
heterogeneous studies should not be meta-analyzed in the first place. However, it has been 
shown that homogeneity is rare and very often falsely assumed, especially for small meta-
analyses, sometimes leading to false conclusions (52). From a statistical point of view it is 
better to identify heterogeneity (which is very likely present anyway) which can then be 
successfully accounted for in a random-effects meta-analysis model(53). There are some 
limitations inherent to the available literature such as: the observational nature of studies, the 
retrospective design of some, the unclear or short follow up periods, the exclusion of patients 
deemed as having too few HbA1c measurements (28)(23)(14)(13)(16)(17) and the non-
adjustment for different numbers of HbA1c measurements, duration of diabetes, 
comorbidities or baseline medications. In addition, there is no accepted method of assessing 
HbA1c variability and a single definition of outcomes was not used. 
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 Our findings support the need for further studies investigating the relationship 
between HbA1c variability and diabetes complications. More sophisticated measures of 
HbA1c variability are needed as well as consensus as to how such variability should be 
defined. These would include adjustment for differing intervals between HbA1c 
measurements and address the temporality of variance problem(54). Our findings suggest that 
HbA1c variability may be a useful risk stratification tool in both type 1 and type 2 diabetes. 
 In conclusion, our meta-analysis shows significant associations between HbA1c 
variability and all-cause mortality, renal and cardiovascular disease in type 2 diabetes and 
with retinopathy, renal and cardiovascular disease in type 1 diabetes. These relationships are 
independent of mean HbA1c and in the majority of studies variability was more predictive of 
adverse outcomes than mean HbA1c. 
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Table 1: Study design and participant characteristics of studies that evaluated glycaemic variability 
 
Study ID Study design; Year; 
Country 
Sample 
size 
Mean age % 
Male 
Inclusion criteria 
Studies of participants with type 1 diabetes 
Hermann 2014 Retrospective cohort study; 
1990 to Mar 2013; Germany 
and Austria. 
35,891 Median age 16 
years. 
52% Participants were included in the German/Austrian Diabetes 
Prospective Documentation Initiative. 
Hietala 2013 Retrospective cohort study; 
1997 to Jan 2012; Finland. 
2,019 No prior laser Rx 
group 35 years. 
Proliferative 
diabetic 
retinopathy group 
39 years. 
49% Participants were adults with type 1 diabetes who took part in 
the FinnDiane study.   
Kilpatrick 2008 Post-hoc analysis of RCT; 
1983 to 1993; USA and 
Canada. 
1,441 27 years 53% Participants were in the Diabetes Control and Complications 
Trials Dataset. 
Marcovecchio 
2011 
Prospective cohort study; 
1986 to 1996 and 2000 to 
2005; UK. 
1,232 Median age at 
diagnosis 9 years. 
55% Participants were in the Oxford Regional Prospective Study 
that included children with type 1 diabetes under the age of 
16 and the Nephropathy Family Study with adolescents aged 
10-16 years with type 1 diabetes. 
Nazim 2014 Cross-sectional study; 1985 to 
2004; Poland. 
438 Mean age at 
diagnosis 9 years. 
55% Participants were children or adolescents with newly 
diagnosed type 1 diabetes who were under the care of the 
endocrinology department of University Children’s Hospital. 
Raman 2011 Retrospective cohort study; 
1993 to 2009; USA and 
Sweden. 
893 Mean age at 
diagnosis 8 years. 
47% Participants were type 1 diabetic paediatric patients in a 
single large tertiary care referral centre. 
Waden 2009 Prospective cohort study; Nov 
1997 to Jan 2009; Finland. 
2,107 36 years. 53% Participants were in the FinnDiane study who had type 1 
diabetes that were diagnosed under the age of 35 with insulin 
treatment initiated within 1 year of diagnosis 
Studies of participants with type 2 diabetes 
Cheng-Chieh 2013 Retrospective cohort study; 
Aug 2002 to Aug 2008; 
Taiwan. 
3,220 57 years. 51% Participants had type 2 diabetes who were at the China 
Medical University Hospital. 
Cummings 2011 Retrospective cohort study; 
1998 to 2008; USA. 
791  54 years. 32% Participants were >18 years of age with type 2 diabetes who 
were seen in one of the primary care practices(family 
medicine, internal medicine)in the South eastern United 
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States. 
Foo 2014 Retrospective cohort study; 
not stated; Singapore. 
234 Not stated Not 
stated 
Participants attended tertiary eye hospital in Singapore and 
had serial HbA1c monitoring for over 2 years. 
Hirakawa 2014 Post hoc analysis of RCT; 
Nov 2001 to 2007; Asia, 
Australasia, Europe, North 
America. 
4,399 66 years. 43% Participants were >55 years of age with a history of major 
macrovascular or microvascular disease or at least one 
vascular disease risk factor from one of 215 collaborating 
centres of the ADVANCE trial. 
Hsu 2012 Post hoc analysis of RCT; 
2003 to 2010; Taiwan. 
821 Age at onset of 
diabetes 51 years.  
46% Participants had type 2 diabetes and were enrolled in the 
Diabetes Management Integrated Delivery System project.  
Lang 2015 Retrospective cohort study; 
not stated; Scotland. 
1,701 Median 74 years. 60% Participants had type 2 diabetes with incident chronic heart 
failure. 
Luk 2013 Prospective cohort study; Jul 
1994 to2009; Hong Kong. 
8,439. 
7184 no 
CKD at 
baseline 
6983 no 
CVD at 
baseline 
58 years. 47% Participants were in the Hong Kong Diabetes Registry. 
Patients with baseline CKD were excluded in the analysis of 
renal endpoint, and patients with baseline CVD were 
excluded in the analysis of cardiovascular endpoint. 
Ma 2012 Retrospective cohort study; 
2003 to 2010; Taiwan. 
881 60 years. 48% Participants were included in the Diabetes Shared Care 
Program at the Cardinal Tien Hospital and attended clinic 
approximately every 3 months. 
Penno 2013 
diabetes care and 
Penno 2013 
Prospective cohort study; 
2007 to 2008; Italy. 
8,260 Median age 68 
years. 
57% Participants were included in the RIACE Italian Multicentre 
Study and participants needed to have 3-5 HbA1c values 
measured serially in a 2 year period.  
Rodriguez 2012 Prospective cohort study, Mar 
1994 to Mar 2009; Spain. 
2,103 59 years. 48% Participants had diabetes and attended outpatient clinics in the 
University Hospital Complex, Santiago de Compostela.  
Skriver 2015 Prospective cohort study; 
1970-2010; Denmark. 
11,205 Median 64 years. 52% Participants were registered with type 2 diabetes on the public 
data files in Aarhus County, Demark who subsequently had at 
least 3 HbA1c measurements. 
Sugawara 2012 Prospective cohort study; 
2000 to 2007; Japan. 
812 55 years. 69% 
 
Participants had type 2 diabetics who were registered on the 
Tsukuba Kawai Diabetes Registry database. 
Takao 2014 Retrospective cohort study, 
1995 to 2012; Japan. 
754 54 years. 82% Participants with type 2 diabetes attending outpatient clinic 
and had been followed up for 2 years with at least 4 HbA1c 
levels. 
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Table 2: Risk of bias among studies which evaluated glycaemic variability and adverse outcomes 
 
Study ID Time frame and number of 
samples used to define HbA1c 
variability. 
Case definition, ascertainment and assessment frequency. <10% loss 
to follow up 
Use of adjustments for potential 
confounders 
Studies of participants with type 1 diabetes 
Hermann 
2014 
Study took place between 1990 to 
March 2013.  Median number of 
HbA1c values per patient during 
one year was 4.3. 
Diabetic retinopathy based on a trained ophthalmologist using 
direct fundoscopy in mydriasis to grade diabetic retinopathy 
according to the modified Airlie House Classification/ETDRS 
standards.  Unclear frequency of evaluation. 
Unclear. Adjusted for age at diabetes diagnosis, 
gender, median HbA1c.  
Hietala 
2013 
Average follow up of 5.2 years. 
10 (IQR 3-18) HbA1c 
measurements per patient. 
Proliferative retinopathy from fundus photographs and/or 
records of dilated slit lamp fundus examination performed by 
a specialist in ophthalmology. Photographs were taken for a 
median of 3 (IQR 1-5) occasions per patient. Proliferative 
retinopathy defined as ≥61 on Early Diabetic Retinopathy 
Treatment Study grading scale. 
Unclear. Adjusted for renal status, diabetes 
duration, mean HbA1c, blood pressure, 
sex and number of HbA1c 
measurements. 
Kilpatrick 
2008 
Average up of 6.5 years. HbA1c 
was measured quarterly but 
unclear number of HbA1c 
measurements per patient. 
Development and progression of diabetic retinopathy defined 
as a change from baseline of ≥3 units on the Early Diabetic 
Retinopathy Treatment Study interim score on any two 
successive annual evaluations.  Nephropathy defined as an 
increase in albumin excretion rate ≥40 mg/24h on any annual 
evaluation providing baseline AER was <40 mg/dl. 
Unclear. Adjusted for age, sex, disease duration, 
randomisation treatment, prevention 
cohort and baseline A1c. 
Marcovec
chio 2011 
The studies took place between 
1986-1996 and 2000-2005. The 
median number of HbA1c 
assessments was 4 (2-16). 
Microalbuminuria was defined as albumin creatinine ratio of 
between 3.5 and 35 mg/mmol for men and 4.0 and 47 
mg/mmol in women in two of three consecutive early morning 
urine samples measured annually. 
Unclear. Adjusted for sex, age at diagnosis, 
chronologic age and mean HbA1c. 
Nazim 
2014 
Follow up of 9.2 years.  Unclear 
number of HbA1c measurements. 
Microalbuminuria defined as albumin excretion rate of ≥20 
µg/min and <200 µg/min in at least two samples obtained 
within 2 or more samples obtained within the period of 3-6 
months. Unclear frequency of urine testing.  
Unclear. Adjusted for age at onset of diabetes, 
presence of arterial hypertension at 
baseline, mean HbA1c and mean insulin 
daily dose. 
Raman 
2011 
Average follow up of 7 years. 
Unclear number of HbA1c 
measurements. 
Microalbuminuria (albumin excretion 
rate≥ 20 mcg/min or microalbumin: creatinine ratio ≥30 
mg/gm Cr). Unclear frequency of urine testing. 
Unclear. Adjusted for age, sex, race and mean 
HbA1c. 
Waden 
2009 
Median follow up of 5.7 years. 
Median number of HbA1c 
measurements per patient was 13 
(IQR 7-20), 2.l3 measurements 
per patient per year. 
Renal status was prospectively assessed by review of all 
recorded values of urine albumin excretion rate and medical 
records.  Progression of renal disease was defined as a shift to 
a higher albuminuria level in any two (of three) consecutive 
urine collection or ends stage renal failure.  Cardiovascular 
Unclear. Adjusted for duration of diabetes, sex, 
blood pressure, total cholesterol, 
smoking, intrapersonal mean of serial 
HbA1c measurements, number of HbA1c 
measurements, diabetic nephropathy and 
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events (myocardial infarction, coronary artery procedure, 
stroke , limb amputation because of ischemia or peripheral 
artery procedure based on medical records at baseline and 
follow up.  Unclear frequency of evaluation. 
baseline cardiovascular events. 
Studies of participants with type 2 diabetes 
Cheng-
Chieh 
2013 
Average follow up of 4.40 year.  
Patients had to have more than 2 
HbA1c measurements for each 
year.  Although not reported, 
patients likely had more than 8 
HbA1c measurements.   
Diabetic nephropathy defined as eGFR<60 ml/min and 
patients followed up regularly every 3 to 6 months. 
Yes. Adjusted for age, sex, lifestyle factors, 
comorbidities, MI, mean FPG, mean 
HbA1c and drug treatments. 
Cummings 
2011 
Average follow up of 7.6 years. 
Patients had to have at least 5 
HbA1c measurements. 
Increase of one or more CKD stages based on baseline and 
most recent follow up visit. 
Unclear. Adjusted for age, race, sex, duration of 
diabetes, blood pressure, drug treatments, 
initial HbA1c and number of HbA1c 
values and fasting blood glucose 
coefficient of variation.  
Foo 2014 Follow up of 2 years with serial 
3-monthly HbA1c (range 3-6) 
values per patient.  
Moderate diabetic retinopathy or worse was assessed using 
retinal photographs of both eyes with a ETDRS level ≥ 43 
after 2 years of HbA1c measurement. 
Unclear. Adjusted for age, gender, ethnicity, 
duration of diabetes, hypertension, 
hyperlipidaemia, smoking, 
microalbuminuria and cardiovascular 
events, mean and standard deviation of 
HbA1c. 
Hirakawa 
2014 
Median study follow up of 3 
years. 5 HbA1c measurements per 
patient. 
Outcomes were composite of major macrovascular (death 
from cardiovascular cause, nonfatal myocardial infarction or 
nonfatal stroke), major microvascular events (new or 
worsening nephropathy or retinopathy) and all-cause 
mortality.  Patients were followed up in trial for first 24 
months and frequency of evaluation unclear. 
Yes. Adjusted for age, sex, randomized blood 
pressure lowering, region, duration of 
diabetes, smoking status, alcohol intake, 
systolic blood pressure, total cholesterol, 
log-transformed triglycerides, BMI, 
medications, mean of HbA1c or fasting 
glucose in the first 24 months.  
Hsu 2012 Average follow up of 6.2 years. 
Bloods was collected every 6 
months but unclear number of 
HbA1c measurements per patient. 
Microalbuminuria was defined as an albumin creatinine ratio 
of 3.4 mg/mmol or higher in two consecutive urine tests.  
Unclear frequency of urine testing. 
Yes. Adjusted for age at diabetes onset, sex, 
education, diabetes duration, smoking 
status, waist circumference, serum lipids, 
mean HbA1c, blood pressure and ACE 
inhibitor or angiotensin receptor blocker 
use. 
Lang 2015 Median follow up of 3.3 years. 
Unclear frequency of evaluation 
or number of HbA1c 
Unclear method of mortality ascertainment. Unclear. Adjusted for significant covariates 
including chronic heart failure duration 
and current drug exposure. 
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measurements.  
Luk 2013 Median follow up 7.2 years. 
Median HbA1c measurements 
was 10 (IQR 5-17). 
Incident chronic kidney disease (eGFR<60ml/min per 
1.73m2) and incident cardiovascular disease (myocardial 
infarction, ischemic heart disease, peripheral vascular disease, 
heart failure, ischaemic stroke) and end stage renal disease 
obtained from Hospital Authority discharge diagnoses. 
Unclear. Adjusted for age, gender, smoking 
history, diabetes duration, BMI, waist 
circumference, blood pressure, serum 
lipids, log urine albumin creatinine ratio, 
eGFR, haemoglobin, and medication use. 
Ma 2012 Average follow up was 4.7 years. 
Average number of HbA1c 
measurements was 12±7. 
Mortality and cause of death obtained from computerized 
death certificates maintained by the Department of Health, 
Executive Yuan in Taiwan. 
Yes. Adjusted for age, gender, BMI, duration 
of diabetes, blood pressure, use of 
antihypertensives, statin, mean LDL 
cholesterol, smoking status, chronic 
kidney disease and mean Ab1c values 
Penno 
2013 
Unclear follow up. Average 
number of HbA1c measurements 
was 4.52±0.76.  Patients had to 
have 3 to 5 HbA1c measurements.   
Diabetic nephropathyby albuminuria and eGFR with unclear 
frequency of evaluation.  Diabetic retinopathy assessed at 
baseline by dilated fundoscopy, unclear follow up evaluation.  
Cardiovascular disease: acute myocardial infarction, stroke, 
foot ulcer or gangrene, amputation, coronary, carotid, and 
lower limb revascularization and surgery for aortic aneurysm 
assessed from medical records were adjudicated based on 
hospital discharge records of specialist visit by an ad hoc 
committee in each center. 
Yes. Adjusted for age, BMI, sex, known 
disease duration, smoking habits, 
triglycerides, HDL cholesterol, 
hypertension, dyslipidemia, previous 
major CVD events, specific diabetes 
treatments, and eGFR and albuminuria 
categories if DR was dependent variable 
or DR categories if renal parameters 
were dependent variable. 
Rodriguez 
2012 
Average follow up of 6.6 years.  
Medan of 10 (IQR 6-14) HbA1c 
measurements per patient. 
Progression of diabetic nephropathy if albumin excretion rate 
was ≥100 mg ⁄ 24 h and had been <40 mg ⁄ 24h at entry, or if 
albumin excretion rate was ≥300 mg⁄ 24 h and had been <200 
mg⁄ 24 h at entry.  Unclear frequency of urine testing. 
Unclear. Adjusted for age, duration of diabetes, 
use of insulin, baseline HbA1c, BMI, 
retinopathy status, use of 
antihypertensive agents, smoking status, 
lipid status, sex, cohort, number of 
HbA1c measurements, and updated 
mean. 
Skriver 
2015 
Median follow up of 6 years. 
Number of HbA1c measurements 
per patient was at least 3. 
All cause-mortality from record linkage with nationwide 
Danish Civil Registration System. 
Unclear. Adjusted for age, gender, medications, 
prior CVD, dementia, chronic pulmonary 
disease, connective tissue disease, ulcer 
disease, mild liver disease, hemiplegia, 
moderate to severe renal disease, 
diabetes with end-organ damage, any 
tumor, leukemia, lymphoma, moderate or 
severe liver disease, metastatic solid 
tumor, AIDS, and index HbA1c. 
Sugawara 
2012 
Average follow up of 4.3 years. 
The median number of HbA1c 
Microalbuminuria was defined as albumin creatinine ratio of 
≥3.4 mg/mmol for at least two of three measurements.  During 
Yes. Adjusted for age, sex, duration of 
diabetes, blood pressure, BMI, serum 
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measurements per patient was 11 
(5-12). 
follow up period albumin creatinine ratio was evaluated every 
6 months. 
lipids, smoking status. 
Takao 
2014 
The median follow up was 15.9 
years.  The median number of 
HbA1c per patient was 79 (40-
117). 
Unclear method of mortality ascertainment and frequency of 
evaluation. 
No, 27.5% 
lost to 
follow up. 
Adjusted for age, sex, mean HbA1c, 
number of HbA1c measurements, 
duration of diabetes, BMI, blood 
pressure, serum lipids and smoking 
status.  
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Table 3: Results of studies which evaluated glycaemic variability and adverse outcomes 
 
Study ID Definition of 
glycaemic 
variability 
Outcomes evaluated Study follow 
up 
Results 
Studies of participants with type 1 diabetes 
Hermann 2014 HbA1c 
coefficient of 
variation. 
Diabetic retinopathy. 1990 to March 
2013 
Cox proportional-hazards multiple regression for diabetic retinopathy with 
HbA1c CV based on people above or below the 50th centile: HR 1.110 (1.10-
1.12). 
 
HbA1c variability led to an additional rise in risk (3.5% higher risk of 
diabetic retinopathy per one unit increase of HbA1c-CV at ten years of 
duration of diabetes. 
Hietala 2013 HbA1c 
coefficient of 
variation. 
Proliferative retinopathy In cohort with 
no prior laser 
treatment 
mean 5.2±2.2 
years. Unclear 
in other 
cohort. 
 
Among participants with verified retinopathy status and indications for laser 
treatment Fine and Gray regression model for risk of proliferative 
retinopathy according to quartiles of HbA1c CV: 
First quartile: HR 1.00 (reference) 
Second quartile: HR 1.3 (0.97-1.8) 
Third quartile: HR 1.5 (1.1-2.0) 
Fourth quartile: HR 1.7 (1.3-2.2) 
Fine and Gray regression model for retinopathy among patients with no prior 
laser treatment requiring laser treatment by HbA1c variability first quartile 
vs fourth quartile: HR 1.6 (1.1-2.5). 
Kilpatrick 2008 HbA1c standard 
deviation. 
Development and progression of 
diabetic retinopathy and 
nephropathy. 
6.5 years. Cox proportional-hazards multiple regression of risk of retinopathy with 
HbA1c SD (1% increase SD): HR 2.11 (1.54-2.89). 
Risk of nephropathy with HbA1c SD (1% increase SD): HR 1.86 (1.41-
2.47). 
Marcovecchio 
2011 
HbA1c standard 
deviation. 
Microalbuminuria. Unclear  Cox proportional-hazards multiple regression for risk of development of 
microalbuminuria by HbA1c SD (for every 1-unit increase in each 
covariate): HR 1.31 (1.01-1.35) 
Nazim 2014 HbA1c 
coefficient of 
variation. 
Microalbuminuria. 9.2 + 3.4 years Cox proportional-hazards multiple regression for risk of developing first 
episode of microalbuminuria by HbA1c CV (per unit increase): HR 1.04 
(1.00-1.08). 
Raman 2011 HbA1c standard 
deviation. 
Micro-albuminuria 
 
7.00+ 2.85 
years 
Cox proportional-hazards multiple regression for microalbuminuria by 
HbA1c SD (per unit increase): HR 1.91 (1.37-2.66) 
Waden 2009 HbA1cstandard 
deviation 
Cardiovascular event and 
progression in renal status (higher 
albuminuria level in any 2 of 3 
Median follow 
up of 5.7 years 
Cox proportional-hazards multiple regression for risk of progression in renal 
status by HbA1c SD (defined according to quartiles of HbA1c SD): HR 1.92 
(1.49- 2.47), risk of cardiovascular event by HbA1c SD (defined according 
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consecutive urine collections or to 
ESRD).  
to quartiles of HbA1c SD): HR 1.98 (1.39- 2.82). 
Studies of participants with type 2 diabetes 
Cheng-Chieh 2013 HbA1c 
coefficient of 
variation (CV). 
Diabetic nephropathy. 4.40 years. Cox proportional-hazards multiple regression for diabetic nephropathy with 
HbA1c CV: 
<6.68: HR 1.00 (reference) 
6.68-13.4: HR 1.18 (0.88-1.58) 
>13.4: HR 1.58 (1.19-2.11) 
Cummings 2011 Average excess 
of HbA1c >7%. 
Increase of one or more CKD 
stages. 
7.6 +1.9 years. Multiple logistic regression model of worsening by one or more chronic 
kidney disease stages with average excess of HbA1c >7%: OR1.173 (1.031-
1.335). 
Foo 2014 HbA1c standard 
deviation. 
Moderate diabetic retinopathy. 2 years. Multivariable logistic regression for moderate diabetic retinopathy with 
HbA1c SD: aOR 1.49 (0.72-3.07). 
Hirakawa 2014 HbA1c 
coefficient of 
variation and 
standard 
deviation. 
Composite of major 
macrovascular (death from 
cardiovascular cause, nonfatal 
myocardial infarction or nonfatal 
stroke) and major microvascular 
events (new or worsening 
nephropathy or retinopathy). 
Microvascular events. 
Macrovascular events. All-cause 
mortality. 
Median 3 
years. 
Cox proportional-hazards multiple regression models 
HbA1c CV 1SD increase and risk of outcomes: 
Macro/micro events: HR 1.11 (1.02-1.21) 
Major macro events: HR 1.18 (1.05-1.34) 
Major micro events: HR 1.07 (0.96-1.2) 
All cause mortality: HR 1.31 (1.16-1.48) 
Continuous HbA1c SD 1SD increase and risk of outcomes: 
Macro/micro events: HR 1.12 (1.02-1.22) 
Major macro events: HR 1.21 (1.06-1.38) 
Major micro events: HR 1.08 (0.96-1.21) 
All cause mortality: HR 1.34 (1.18-1.53) 
Hsu 2012 HbA1c standard 
deviation. 
Development of 
microalbuminuria. 
6.2 years. Cox proportional-hazards multiple regression for incidence of 
microalbuminuria with HbA1c SD quartiles: 
Quartile 1; HR 1.00 (reference) 
Quartile 2: HR 1.03 (0.72-1.48) 
Quartile 3: HR 1.09 (0.75-1.57) 
Quartile 4: HR 1.48 (1.03-2.12)     
Lang 2015 HbA1c 
coefficient of 
variation. 
All-cause mortality. Median follow 
up 3.3 years 
(0.9-7.5). 
Cox proportional-hazards multiple regression for mortality with 0.01 
increase in CV:  
From 0.036 (Q1) to 0.046 was aHR 1.04 (1.02-1.07).  
From 0.064 (Q2) to 0.074 was aHR 1.03 (1.01-1.05).  
From 0.11 (Q3) to 0.12 was aHR 1.02 (1.01-1.03). 
Luk 2013 HbA1c standard 
deviation. 
Incident chronic kidney disease 
(eGFR<60ml/min per 1.73m2), 
incident cardiovascular disease 
Median follow 
up of 7.2 
years. 
Cox proportional-hazards multiple regression for risk of adverse outcome 
with adjusted HbA1c SD: 
Incident chronic kidney disease: HR 1.16 (1.10-1.22). End stage renal 
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(MI, IHD, PVD, HF, ischaemic 
stroke) and end stage renal 
disease. 
failure: HR 1.53 (1.35–1.73). Incident cardiovascular disease: HR1.27 (1.15–
1.40). 
Ma 2012 HbA1c standard 
deviation and 
coefficient of 
variation. 
All cause mortality. 4.7 + 2.3 
years. 
Cox proportional-hazards multiple regression for risk of all-cause mortality 
with HbA1c SD (>50th centile vs<50th centile):HR 1.99 (1.11-3.54) and 
HbA1c coefficient of variation (>50th centile vs<50th centile): HR 1.06 (1.01- 
1.11). 
Penno 2013 HbA1c  
standard 
deviation. 
Diabetic nephropathyby 
albuminuria and eGFR. Diabetic 
retinopathy. 
Cardiovascular disease; acute 
myocardial infarction (AMI), 
stroke, foot ulcer or gangrene, 
amputation, coronary, carotid, and 
lower limb revascularization and 
surgery for aortic aneurysm. 
Unclear Multiple logistic regression of outcomes by HbA1c SD quartiles: 
Microalbuminuria 
Quartile 1: OR 1.00 (reference) 
Quartile 2: OR 1.03 (0.878-1.22) 
Quartile 3: OR 1.14 (0.968-1.35) 
Quartile 4: OR 1.31 (1.10-1.56) 
Macroalbuminuria 
Quartile 1: OR 1.00 (reference) 
Quartile 2: OR 0.939 (0.672-1.31) 
Quartile 3: OR 1.04 (0.757-1.44) 
Quartile 4: OR 1.41 (1.03-1.93) 
eGFR<60 ml/min/1.73m2 
Quartile 1: OR 1.00 (reference) 
Quartile 2: OR 1.00 (0.838-1.20) 
Quartile 3: OR 1.23 (1.03-1.48) 
Quartile 4: OR 1.24 (1.02-1.51) 
Multiple logistic regression 1% increment of HbA1c SD non-advanced 
diabetic retinopathy vs no retinopathy OR 0.917 (0.758-1.11)  
Multiple logistic regression of HbA1c - SD quartiles and 
ulceration/gangrene: 
Quartile 1: OR 1(reference) 
Quartile 2: OR 1.06 (0.736-1.52)  
Quartile 3: OR 1.02 (0.709-1.46)  
Quartile 4: OR 1.50 (1.06-2.12)  
Rodriguez 2012 HbA1c standard 
deviation and 
coefficient of 
variation. 
Progression of diabetic 
nephropathy; if albumin excretion 
rate was ≥ 100 mg ⁄ 24 h and had 
been < 40 mg ⁄ 24 h at entry, or if 
albumin excretion rate was ≥ 300 
mg⁄ 24 h and had been < 200 mg⁄ 
24 h at entry. 
6.6 years Cox proportional-hazards multiple regression for risk of progression of 
nephropathy by HbA1c SD (per 11 mmol/mol (1%) increase): HR 1.37 
(1.12-1.69) and HbA1c CV: HR 1.03 (1.01-1.04). 
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Skriver 2015 Mean absolute 
residual around 
the line 
connecting 
index value and 
closing value. 
All-cause mortality. 6 years. For index HbA1c ≤8% (64 mmol/mol), variability above 0.5 was associated 
with increased mortality HR 1.3 (1.1-1.5) per HbA1c percentage point 
variability. 
 
For individuals with index HbA1c>8% (64 mmol/mol), no association 
between HbA1c variability and mortality could be identified 
Sugawara 2012 HbA1c standard 
deviation. 
Microalbuminuria. 4.3 + 2.7 
years. 
Cox proportional-hazards multiple regression for risk of microalbuminuria 
by incremental HbA1c SD (per 1 SD increment): HR 1.20 (1.03- 1.39). 
Takao 2014 HbA1c standard 
deviation and 
coefficient of 
variation. 
All cause mortality. Median follow 
up time 15.9 
years. 
Cox proportional-hazards multiple regression for risk of all cause mortality 
with HbA1c SD: HR 3.17 (1.43-7.03) and HbA1c CV: HR 1.10 (1.04-1.16). 
Cox proportional–hazards multiple regression models for all-cause mortality, 
HbA1c SD tertiles HR (95% CI) 
Tertile 1; 1 
Tertile 2; 1.45 (0.730-2.88) 
Tertile 3; 3.09 (1.45-6.58) 
Cox proportional–hazards multiple regression models for all-cause mortality, 
HbA1c CV tertiles HR (95% CI) 
Tertile 1; 1 
Tertile 2; 1.21 (0.616-2.38) 
Tertile 3; 2.89 (1.45-5.74) 
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Figure 1: Flow diagram of study selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2372 studies found from 
MEDLINE and EMBASE 
search 
 
65 potentially relevant 
studies from titles and 
abstract screening 
 
20 studies met the final 
inclusion criteria after 
reviewing full manuscripts 
 
2307 studies were excluded since did not evaluate 
outcomes of interest or include HbA1c variability or 
included participants without diabetes/with 
gestational diabetes/with prediabetes or were in 
vivo/in vitro studies or incorrect study type or not 
available in English 
45 studies were excluded since did not evaluate 
outcomes of interest or include HbA1c variability or 
included participants without diabetes/with 
gestational diabetes/with prediabetes or were in 
vivo/in vitro studies or incorrect study type or were 
not available in English or were not able to obtain 
full paper with insufficient details from the abstract 
to allow inclusion.  
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 Appendix 1: Search Strategy 
Interface: OvidSP 
Databases: MEDLINE and EMBASE from inception to 23rd July 2015 
Search Terms: 
1     diabetes mellitus.ab,ti. 
2     (Myocardial infarction or Ischemic heart disease or Ischaemic heart disease or acute 
coronary syndrome or coronary artery disease or stroke or cerebrovascular disease or 
cerebrovascular accident or heart failure or cardiac failure or left ventricular impairment or 
death or mortality or diabetic retinopathy or renal failure or kidney failure or nephropathy or 
diabetic neuropathy or chronic kidney disease or microalbuminuria or proteinuria or 
cardiovascular disease or peripheral vascular disease).ab,ti. 
3     (A1c variability or HbA1c variability or variation in glycosylated hemoglobin A1c or 
variation in glycosylated haemoglobin A1c or glycaemic variability or glycaemic control or 
glycemic control or glycemic variability).ab,ti.  
4      1 AND 2 AND 3 
5     limit 4 to yr="2004 -Current" 
6     remove duplicates from 5 
 
The restrictions are ab.ti which refer to the presence of the requested search term in the title 
or abstract. 
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Appendix 2: Forest Plots 
 
Figure 2: Type 1 diabetes and risk of adverse outcomes by HbA1c variability based on 
coefficient of variation and standard deviation 
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Figure 3: Type 2 diabetes and risk of adverse outcomes by HbA1c variability based on coefficient of 
variation 
A ) Type 2 diabetes risk of adverse outcomes with high vs. low CV 
 
 
 
 
 
 
 
 
 
B) Type 2 diabetes risk of adverse outcomes with incremental increase in CV 
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Figure 4: Type 2 diabetes and risk of adverse outcomes by HbA1c variability based on standard 
deviation 
A) Type 2 diabetes risk of adverse outcomes with high vs. low SD 
 
 
 
 
 
 
 
 
 
B) Type 2 diabetes risk of adverse outcomes with incremental increase in SD 
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Supplementary Table 1: Sensitivity analysis for type 1 diabetes 
Sensitivity analysis for type 1 diabetes No. of studies RR (95% CI) 
Prospective studies only (n=2) 
High vs low SD and risk of nephropathy 1 1.92 (1.49-2.47) 
High vs low SD and risk of CV events 1 1.98 (1.39-2.82) 
Incremental increase in SD and risk of 
microalbuminuria 
1 1.31 (1.01-1.70) 
Studies that adjusted for duration of diabetes (n=3) 
High vs low CV and risk of diabetic retinopathy  1 1.70 (1.31-2.21) 
High vs low SD and risk of nephropathy  1 1.92 (1.49-2.47) 
High vs low SD and risk of CV events 1 1.98 (1.39-2.82) 
Incremental increase in SD and risk of nephropathy  1 1.86 (1.41-2.46) 
Incremental increase in SD and risk of retinopathy  1 2.11 (1.54-2.89) 
Studies that adjusted for number of HbA1c measurements (n=2) 
High vs low CV and risk of diabetic retinopathy  1 1.70 (1.31-2.21) 
High vs low SD and risk of nephropathy  1 1.92 (1.49-2.47) 
High vs low SD and risk of CV events 1 1.98 (1.39-2.82) 
Studies that adjusted for 1 or more comorbidities (n=3) 
High vs low CV and risk of diabetic retinopathy 1 1.70 (1.31-2.21) 
Incremental increase in CV and risk of 
microalbuminuria 
1 1.04 (1.00-1.08) 
High vs low SD and risk of nephropathy  1 1.92 (1.49-2.47) 
High vs low SD and risk of CV events 1 1.98 (1.39-2.82) 
Studies that had duration longer than 5 years (n=6) 
High vs low CV and risk of diabetic retinopathy 2 1.34 (0.89-2.04) 
Incremental increase in CV and risk of 
microalbuminuria 
1 1.04 (1.00-1.08) 
High vs low SD and risk of nephropathy  1 1.92 (1.49-2.47) 
High vs low SD and risk of CV events 1 1.98 (1.39-2.82) 
Incremental increase in SD and risk of nephropathy 1 1.86 (1.41-2.46) 
Incremental increase in SD and risk of 
microalbuminuria  
1 1.91 (1.37-2.66) 
Incremental increase in SD and risk of retinopathy  1 2.11 (1.54-2.89) 
Studies that adjusted for baseline medications (n=2) 
Incremental increase in CV and risk of 
microalbuminuria 
1 1.04 (1.00-1.08) 
Incremental increase in SD and risk of nephropathy 1 1.86 (1.41-2.46) 
Incremental increase in SD and risk of retinopathy  1 2.11 (1.54-2.89) 
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Supplementary Table 2: Sensitivity analysis for type 2 diabetes 
Sensitivity analysis for type 2 diabetes No. of studies RR (95% CI) 
Prospective studies only (n=4) 
Incremental increase in CV and nephropathy 1 1.03 (1.01-1.05) 
High vs low SD and nephropathy (including decline in 
eGFR) 
1 1.24 (1.02-1.51) 
High vs low SD and microalbuminuria 1 1.31 (1.10-1.56) 
High vs low SD and macroalbuminuria 1 1.41 (1.03-1.93) 
High vs low SD and ulceration/gangrene 1 1.50 (1.06-2.12) 
Incremental SD and nephropathy (including CKD) 2 1.22 (1.05-1.42) 
Incremental SD and end stage renal failure 1 1.53 (1.35-1.73) 
Incremental SD and microalbuminuria 1 1.20 (1.03-1.39) 
Incremental SD and retinopathy 1 0.92 (0.76-1.11) 
Incremental SD and cardiovascular disease 1 1.27 (1.15-1.40) 
Studies that adjusted for duration of diabetes (n=9) 
High vs low CV and mortality 2 1.65 (0.62-4.35) 
Incremental CV and nephropathy 1 1.03 (1.01-1.05) 
Incremental CV and macro/microvascular events 1 1.11 (1.02-1.21) 
Incremental CV and macrovascular events 1 1.18 (1.04-1.33) 
Incremental CV and microvascular events 1 1.07 (0.96-1.20) 
Incremental CV and mortality 2 1.19 (1.00-1.41) 
High vs low SD and nephropathy (including decline in 
eGFR) 
1 1.24 (1.02-1.51) 
High vs low SD and microalbuminuria 2 1.34 (1.15-1.57) 
High vs low SD and macroalbuminuria 1 1.41 (1.03-1.93) 
High vs low SD and ulceration/gangrene 1 1.50 (1.06-2.12) 
High vs low SD and mortality 2 2.34 (1.48-3.71) 
Incremental SD and nephropathy (including CKD) 2 1.22 (1.05-1.42) 
Incremental SD and end stage renal failure 1 1.53 (1.35-1.73) 
Incremental SD and microalbuminuria 1 1.20 (1.03-1.39) 
Incremental SD and retinopathy 2 1.03 (0.69-1.53) 
Incremental SD and macro/microvascular events 1 1.12 (1.02-1.22) 
Incremental SD and macrovascular events 1 1.21 (1.06-1.38) 
Incremental SD and microvascular events 1 1.08 (0.96-1.21) 
Incremental SD and cardiovascular disease 1 1.27 (1.15-1.40) 
Incremental SD and mortality 2 1.88 (0.82-4.27) 
Studies that adjusted for number of HbA1c measurements (n=2) 
High vs low CV and mortality 1 2.89 (1.45-5.74) 
Incremental CV and nephropathy 1 1.03 (1.01-1.05) 
Incremental CV and mortality 1 1.10 (1.03-1.16) 
High vs low SD and mortality 1 3.09 (1.45-6.58) 
Incremental SD and nephropathy (including CKD) 1 1.37 (1.12-1.68) 
Incremental SD and mortality 1 3.17 (1.43-7.03) 
Studies that adjusted for 1 or more comorbidities (n=5) 
High vs low CV and diabetic nephropathy 1 1.58 (1.19-2.10) 
High vs low CV and mortality 1 1.06 (1.01-1.11) 
Incremental CV and nephropathy 1 1.03 (1.01-1.05) 
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High vs low SD and nephropathy (including decline in 
eGFR) 
1 1.24 (1.02-1.51) 
High vs low SD and microalbuminuria 1 1.31 (1.10-1.56) 
High vs low SD and macroalbuminuria 1 1.41 (1.03-1.93) 
High vs low SD and ulceration/gangrene 1 1.50 (1.06-2.12) 
High vs low SD and mortality 1 1.99(1.11-3.55) 
Incremental SD and nephropathy (including CKD) 1 1.37 (1.12-1.68) 
Incremental SD and retinopathy 2 1.03 (0.69-1.53) 
Studies that had duration longer than 5 years (n=4) 
High vs low CV and mortality 1 2.89 (1.45-5.74) 
Incremental CV and nephropathy 1 1.03 (1.01-1.05) 
Incremental CV and mortality 1 1.10 (1.03-1.16) 
High vs low SD and microalbuminuria 1 1.48 (1.03-2.12) 
High vs low SD and mortality 1 3.09 (1.45-6.58) 
Incremental SD and nephropathy (including CKD) 2 1.22 (1.05-1.42) 
Incremental SD and end stage renal failure 1 1.53 (1.35-1.73) 
Incremental SD and cardiovascular disease 1 1.27 (1.15-1.40) 
Incremental SD and mortality 1 3.17 (1.43-7.03) 
Studies that had duration shorter than 5 years (n=4) 
High vs low CV and diabetic nephropathy 1 1.58 (1.19-2.10) 
High vs low CV and mortality 1 1.06 (1.01-1.11) 
Incremental CV and macro/microvascular events 1 1.11 (1.02-1.21) 
Incremental CV and macrovascular events 1 1.18 (1.04-1.33) 
Incremental CV and microvascular events 1 1.07 (0.96-1.20) 
Incremental CV and mortality 1 1.31 (1.16-1.48) 
High vs low SD and mortality 1 1.99 (1.11-3.55) 
Incremental SD and microalbuminuria 1 1.20 (1.03-1.39) 
Incremental SD and retinopathy 1 1.49 (0.72-3.07) 
Incremental SD and macro/microvascular events 1 1.12 (1.02-1.22) 
Incremental SD and macrovascular events 1 1.21 (1.06-1.38) 
Incremental SD and microvascular events 1 1.08 (0.96-1.21) 
Incremental SD and mortality 1 1.34 (1.18-1.53) 
Studies that adjusted for baseline medications (n=7) 
High vs low CV and diabetic nephropathy 1 1.58 (1.19-2.10) 
High vs low CV and mortality 1 1.06 (1.01-1.11) 
Incremental CV and nephropathy 1 1.03 (1.01-1.05) 
Incremental CV and macro/microvascular events 1 1.11 (1.02-1.21) 
Incremental CV and macrovascular events 1 1.18 (1.04-1.33) 
Incremental CV and microvascular events 1 1.07 (0.96-1.20) 
Incremental CV and mortality 1 1.31 (1.16-1.48) 
High vs low SD and nephropathy (including decline in 
eGFR) 
1 1.24 (1.02-1.51) 
High vs low SD and mortality 1 1.99 (1.11-3.55) 
High vs low SD and microalbuminuria 2 1.34 (1.15-1.57) 
High vs low SD and macroalbuminuria 1 1.41 (1.03-1.93) 
High vs low SD and ulceration/gangrene 1 1.50 (1.06-2.12) 
Incremental SD and nephropathy(including CKD) 2 1.22 (1.05-1.42) 
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Incremental SD and end stage renal failure 1 1.53 (1.35-1.73) 
Incremental SD and retinopathy 1 0.92 (0.76-1.11) 
Incremental SD and cardiovascular disease 1 1.27 (1.15-1.40) 
Incremental SD and macro/microvascular events 1 1.12 (1.02-1.22) 
Incremental SD and macrovascular events 1 1.21 (1.06-1.38) 
Incremental SD and microvascular events 1 1.08 (0.96-1.21) 
Incremental SD and mortality 1 1.34 (1.18-1.53) 
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